Sanofi recalls heartburn drug over cancer risks

Sanofi is recalling Zantac in the U.S. a month after the FDA warned the heartburn drug contained a possible carcinogen.

Several of the country's largest retailers, including Walmart, CVS and Walgreens, pulled Zantac and other ranitidine products off their shelves several weeks ago.

Sanofi said it is initiating the recall because of "inconsistencies in preliminary test results of the active ingredient used in the U.S," according to a news release.

Sanofi's decision to pull Zantac comes as regulators are trying to figure out why N-nitrosodimethylamine, a possible carcinogen, was found in some ranitidine medicines. A growing number of regulators around the world have also either banned the drugs or asked manufacturers to conduct recalls.

Read the full news release here.

More articles on pharmacy:
Novant Health to open health clinics inside Walgreens
GlaxoSmithKline recalls prescription heartburn drug globally
BIO CEO to step down at the end of 2020

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers